Literature DB >> 15755289

Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies.

Claire Pouplard1, Marc Antoine May, Sandra Regina, Michel Marchand, Jacques Fusciardi, Yves Gruel.   

Abstract

Cardiopulmonary bypass (CPB) induces the release of platelet factor 4 (PF4) and patients are at risk of heparin-induced thrombocytopenia (HIT). This study was aimed to determine whether an abnormal evolution in platelet count (PC) after CPB is predictive of the development of HIT antibodies. Two abnormal PC patterns were defined: pattern P1, characterized by a decrease in PC following previous correction of thrombocytopenia occurring during CPB, and pattern P2, defined as a persistent low PC in the days following CPB. PC was evaluated for 10 d in 305 consecutive patients before and after CPB. Serotonin release assay (SRA) was carried out between days 8 and 10 to detect pathogenic heparin-dependent antibodies. Moreover, antibodies to heparin-PF4 (H-PF4) complexes were assayed by enzyme-linked immunosorbent assay. PC evolution after CPB was normal in 300 patients although antibodies to H-PF4 were frequently present (53.4%). Changes in PC were abnormal in five patients with pattern P1 (n = 4) or P2 (n = 1). As SRA was positive in four of the five cases, the positive predictive value of abnormal PC pattern for pathogenic HIT antibodies was 80%. Careful follow-up of PC after CPB makes it possible to predict with high specificity (99%) for those patients who develop pathogenic HIT antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755289     DOI: 10.1111/j.1365-2141.2005.05381.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.

Authors:  Thomas Gremmel; Karin Frühwirth; Christoph W Kopp; Alexandra Kaider; Sabine Steiner; Tamam Bakchoul; Ulrich J H Sachs; Renate Koppensteiner; Simon Panzer
Journal:  Clin Res Cardiol       Date:  2012-01-11       Impact factor: 5.460

2.  Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.

Authors:  Janice McFarland; Andrew Lochowicz; Richard Aster; Bryan Chappell; Brian Curtis
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

3.  Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.

Authors:  Nicole L Whitlatch; David F Kong; Ara D Metjian; Gowthami M Arepally; Thomas L Ortel
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

Review 4.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  [Cardiopulmonary bypass in cardiac surgery].

Authors:  T Baehner; O Boehm; C Probst; B Poetzsch; A Hoeft; G Baumgarten; P Knuefermann
Journal:  Anaesthesist       Date:  2012-10       Impact factor: 1.041

6.  Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study.

Authors:  Jack C J Sun; Kevin H T Teoh; Tej Sheth; David Landry; Hyejung Jung; Theodore E Warkentin; Salim Yusuf; Andre Lamy; John W Eikelboom
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

7.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

8.  Optical density values correlate with the clinical probability of heparin induced thrombocytopenia.

Authors:  Brendan M Weiss; Nathan M Shumway; Robin S Howard; Lloyd K Ketchum; Thomas J Reid
Journal:  J Thromb Thrombolysis       Date:  2007-11-04       Impact factor: 2.300

9.  Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.

Authors:  Nicole L Whitlatch; Stephanie L Perry; Thomas L Ortel
Journal:  Thromb Haemost       Date:  2008-10       Impact factor: 5.249

10.  Atherosclerosis is not a risk factor for anti-platelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery.

Authors:  Adam Cuker; Lubica Rauova; Douglas Bolgiano; William H Matthai; Mortimer Poncz; Barbara A Konkle
Journal:  Thromb Haemost       Date:  2014-01-30       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.